Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library

Semaglutide vs survodutide

Semaglutide is an FDA-approved GLP-1 receptor agonist, and survodutide is an investigational peptide that activates both the GLP-1 receptor and the glucagon receptor 1,2,3. They have been compared directly in a 16-week phase 2 trial in type 2 diabetes that included an open-label semaglutide arm 4, and in obese mice (animal data) 5. No phase 3 head-to-head trial was identified 6.

Unbranded reference vial illustrating Semaglutide; not an actual product
Semaglutide
FDA-approved
Unbranded reference vial illustrating Survodutide; not an actual product
Survodutide
Investigational

Side by side

FieldSemaglutideSurvodutide
ClassGLP-1 receptor agonist 1Dual glucagon receptor and GLP-1 receptor agonist (investigational) 3
Origin and structureGLP-1 analogue with 94% homology to human GLP-1 and a C18 fatty diacid at lysine 26 for albumin binding 1Acylated peptide carrying a C18 fatty acid as a half-life-extending element 5
Proposed mechanismActivates the GLP-1 receptor, a regulator of appetite and calorie intake 1Activates glucagon and GLP-1 receptors; in mice, reduced food intake and increased energy expenditure 5
Half-lifeAbout 1 week per the FDA labels 1,7Not located in the sources reviewed
Highest human trial phaseApproved; phase 3 and outcome trials published 8,9,10Phase 3 (SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-MASLD) 3,11,12
FDA statusApproved as Ozempic (5 December 2017) and Wegovy (4 June 2021), per Drugs@FDA as of 24 October 2026 2Not approved; no Drugs@FDA application record as of 24 October 2026 13
Published human outcomesSTEP 1: -14.9% vs -2.4% at 68 weeks 8; SELECT: cardiovascular events hazard ratio 0.80 9; FLOW: 24% lower risk of major kidney events 10SYNCHRONIZE-1: -12.2% and -13.0% vs -5.4% at 76 weeks 3; SYNCHRONIZE-2: -8.2% and -9.8% vs -3.9% 11
Safety signalsBoxed warning for thyroid C-cell tumours seen in rodents; gastrointestinal reactions most common 1; more retinopathy complications in SUSTAIN-6 14Gastrointestinal events in 80.9% and 89.7% vs 47.9% with placebo in SYNCHRONIZE-1 3; adverse events in 77.8% vs 52.0% with semaglutide in the phase 2 comparison 4
WADA statusNot named on the 2026 Prohibited List 15; GLP-1 receptor agonist status unchanged for 2027 per WADA 16Not named on the 2026 Prohibited List; class S0 covers drugs under clinical development with no current approval by any governmental health authority 15
Who funded the evidenceNovo Nordisk 8,9,10Boehringer Ingelheim, including the phase 2 trial with a semaglutide arm 3,4

Semaglutide: what the data says

Semaglutide is FDA-approved for type 2 diabetes, cardiovascular and kidney risk reduction in specified groups, chronic weight management and, under accelerated approval, MASH with moderate to advanced fibrosis 1,7.

  • In STEP 1 (1961 adults without diabetes; human data), mean body-weight change at 68 weeks was -14.9% vs -2.4% with placebo 8.
  • In SELECT (17,604 adults with cardiovascular disease; human data), the primary cardiovascular outcome occurred in 6.5% vs 8.0% with placebo 9.
  • In FLOW (3533 adults with type 2 diabetes and chronic kidney disease; human data), major kidney disease events were 24% lower than with placebo 10.

Survodutide: what the data says

Survodutide has completed phase 3 trials in obesity, type 2 diabetes with obesity, and MASLD 3,11,12.

  • In SYNCHRONIZE-1 (725 adults; human data), mean body-weight change at 76 weeks was -12.2% and -13.0% vs -5.4% with placebo 3.
  • In a 16-week phase 2 trial in 413 people with type 2 diabetes on metformin (human data), HbA1c reductions were similar between a low survodutide dose and open-label semaglutide (-1.46% vs -1.47%), while body-weight change reached -8.7% with survodutide vs -5.3% with semaglutide 4.
  • In obese mice (animal data), survodutide produced larger body-weight reductions than semaglutide at doses giving its maximal response, attributed to added energy expenditure 5.

Key research differences

  • Receptor targets: semaglutide acts only on the GLP-1 receptor, while survodutide also activates the glucagon receptor 1,3.
  • Regulatory status: semaglutide has been FDA-approved since 2017; survodutide had no Drugs@FDA record on 24 October 2026 2,13.
  • Direct phase 2 comparison: in type 2 diabetes over 16 weeks, HbA1c change was similar at a low survodutide dose, and body-weight change was larger at higher survodutide doses than with open-label semaglutide 4.
  • Adverse events in that comparison: reported by 77.8% of survodutide-treated participants vs 52.0% on semaglutide, mainly gastrointestinal 4.
  • Outcome trials: semaglutide has published cardiovascular (SELECT) and kidney (FLOW) outcome trials; no comparable outcome trial results for survodutide were located 9,10.

Where the evidence is limited

The only human head-to-head data come from a 16-week phase 2 trial in which the semaglutide arm was open-label and used doses up to 1.0 mg weekly, so it does not reflect longer-term use or the higher dose approved for weight management 4. The mouse comparison is animal data only 5. The phase 3 trials of each drug used different durations and populations, and each programme was funded by its developer 3,4,8.

Frequently asked questions

Has survodutide been compared with semaglutide?
Yes, in a 16-week phase 2 trial in type 2 diabetes: HbA1c reductions were similar for a low survodutide dose and semaglutide, and body-weight change was larger with higher survodutide doses, with more adverse events 4.
Does survodutide lead to more body-weight change than semaglutide?
The evidence does not settle this. The only human comparison was short, used an open-label semaglutide arm (up to 1.0 mg weekly) and was sponsored by survodutide's developer 4.
Is survodutide FDA-approved?
No. No Drugs@FDA application record was returned on 24 October 2026, and its 2026 phase 3 reports describe it as investigational 3,13.

References

  1. WEGOVY (semaglutide) injection and tablets: prescribing information, DailyMed set ID ee06186f-2aa3-4990-a760-757579d8f77b (label version dated 18 June 2026) FDA label (via openFDA). 2026
  2. Drugs@FDA application records for NDA 215866 (Mounjaro), NDA 217806 (Zepbound), NDA 209637 (Ozempic), NDA 215256 (Wegovy), NDA 022341 (Victoza) and NDA 206321 (Saxenda): original approval dates (queried 24 October 2026) Drugs@FDA (via openFDA). 2026
  3. Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1) N Engl J Med. 2026
  4. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Diabetologia. 2024
  5. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy Mol Metab. 2022
  6. ClinicalTrials.gov registry search for survodutide as intervention (29 records, 12 phase 3; retrieved 24 October 2026) ClinicalTrials.gov. 2026
  7. OZEMPIC (semaglutide) injection: prescribing information, DailyMed set ID adec4fd2-6858-4c99-91d4-531f5f2a2d79 (label version dated 1 June 2026) FDA label (via openFDA). 2026
  8. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) N Engl J Med. 2021
  9. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) N Engl J Med. 2023
  10. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) N Engl J Med. 2024
  11. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes (SYNCHRONIZE-2) N Engl J Med. 2026
  12. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Nat Med. 2026
  13. Drugs@FDA application data queried through openFDA for survodutide (no matching application record returned on 24 October 2026) openFDA / Drugs@FDA. 2026
  14. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) N Engl J Med. 2016
  15. The 2026 Prohibited List - World Anti-Doping Code, as published in the Netherlands Treaty Series (Tractatenblad 2026, 25; Council of Europe Anti-Doping Convention appendix, in force 1 January 2026) Tractatenblad (Official Publications of the Kingdom of the Netherlands). 2026
  16. WADA publishes 2027 Prohibited List (news release, 21 September 2026) World Anti-Doping Agency. 2026

For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page compares published research and is not medical advice or a recommendation.